RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/27323777http://www.w3.org/2000/01/rdf-schema#comment"The human TESTIN (TES) gene has been identified as a candidate tumor suppressor based on its location at a common fragile site - a region where loss of heterozygosity has been detected in numerous types of tumors. To investigate its role in colorectal cancer (CRC), we examined TES protein levels in CRC tissue samples and cell lines. We observed that TES was markedly reduced in both CRC tissue and cell lines. Additionally, overexpression of TES significantly inhibited cell proliferation, migration, and invasion, while increasing cell apoptosis in colon cancer cells. By contrast, shRNA-mediated TES knockdown elicited the opposite effects. TES inhibited the progression of CRC by up-regulating pro-apoptotic proteins, down-regulating anti-apoptotic proteins, and simultaneously activating p38 mitogen-activated protein kinase (MAPK) signaling pathways. Collectively, these data indicate that TES functions as a necessary suppressor of CRC progression by activating p38-MAPK signaling pathways. This suggests that TES may have a potential application in CRC diagnosis and targeted gene therapy."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.org/dc/terms/identifier"doi:10.18632/oncotarget.9961"xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Gao L."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Huang K."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Li H."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Liu H."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Niu Y."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Wang J."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Wang G."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Wang Z."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Wang L."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/author"Wang L.'"xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/date"2016"xsd:gYear
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/name"Oncotarget"xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/pages"45819-45836"xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/title"TES inhibits colorectal cancer progression through activation of p38."xsd:string
http://purl.uniprot.org/citations/27323777http://purl.uniprot.org/core/volume"7"xsd:string
http://purl.uniprot.org/citations/27323777http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/27323777
http://purl.uniprot.org/citations/27323777http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/27323777
http://purl.uniprot.org/uniprot/#_E0X098-mappedCitation-27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27323777
http://purl.uniprot.org/uniprot/#_B2RDR4-mappedCitation-27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27323777
http://purl.uniprot.org/uniprot/#_B7Z6L5-mappedCitation-27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27323777
http://purl.uniprot.org/uniprot/#_A4D0U5-mappedCitation-27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27323777
http://purl.uniprot.org/uniprot/#_B7Z5L5-mappedCitation-27323777http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27323777